


3



Patent

Docket Number: PUR-00114.P.1.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)
)
Raucy)
)
Application No.: 09/832,621)
)
Filed: April 11, 2001)
)
For: COMPOSITIONS AND)
METHODS FOR INDUCTION OF)
PROTEINS INVOLVED IN)
XENOBIOTIC METABOLISM)
)

Examiner: To Be Determined

Art Unit: To Be Determined

Assistant Commissioner for Patents
Washington D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the attached Form PTO 1449, copies of which are enclosed.


This statement is being filed before the mailing of a First Office Action on the merits under 37 C.F.R. § 1.97(a)(3). Accordingly, no fee under 37 C.F.R. § 1.17(p) is deemed necessary.

Information Disclosure Statement
PUR-00114.P.1.1
Raucy

Please apply any charges not covered, or any credits, to Deposit Account number 501321 in the name of David R. Preston & Associates, having Customer Number 24232.

Respectfully submitted,

Date: August 30, 2001




David R. Preston
Reg. No. 38,710

David R. Preston & Associates
12625 High Bluff Drive
Suite 205
San Diego, CA 92130
phone: 858.724.0375
facsimile: 858.724.0384

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)


SEP 04 2001




TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number:	09/832,621
		Filing Date:	April 11, 2001
		First Named Inventor:	Raucy
		Group Art Unit:	To Be Determined
		Examiner:	To Be Determined
Total Pages in This Submission:	7	Attorney Docket Number:	PUR-00114.P.1.1

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal, Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits / Declarations(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Requests	<input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address	<input type="checkbox"/> Additional Inclosures, identified below: Postcard Form 1449 and Cited References
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts / Incomplete Application	Remarks:	
<input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual Name	David R. Preston
Signature	
Date	August 30, 2001

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date.			Date: 8/30/01
Typed or printed name:	David R. Preston		
Signature		Date:	8/30/01

FEE TRANSMITTAL		Complete if Known	
Patent fees are subject to annual revision on October 1. These are the fees effective October 1, 1997. Small Entity payments <u>must</u> be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/09-12. See 37 C.F.R. §§ 1.27 and 1.28.		Application Number:	09/832,621
		Filing Date:	April 11, 2001
		First Named Inventor:	Raucy
		Group / Art Unit:	To Be Determined
Total Amount in Payment	\$ 0.00	Docket Number:	PUR-00114.P.1.1


METHOD OF PAYMENT
1. <input type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any over payments to: Deposit Account Number: <input type="checkbox"/> Deposit Account Name: <input type="checkbox"/> <input type="checkbox"/> Charge Any Additional Fee Required Under 37 C.F.R. §§ 1.16 and 1.17 to <u>Deposit Account Number 50132</u> <input type="checkbox"/> Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mailing of the Notice of Allowance.
2. <input type="checkbox"/> Payment Enclosed <input type="checkbox"/> Check Number <input type="checkbox"/> Money Order <input type="checkbox"/> Other

FEE CALCULATION						
1. BASIC FILING FEE						
	Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
	101		201		Utility Filing Fee	\$
	106		206		Design Filing Fee	\$
	107		207		Plant Filing Fee	\$
	108		208		Reissue Filing Fee	\$
	114		214		Provisional Filing Fee	\$
SUBTOTAL (1)						\$ 0.00

2. EXTRA CLAIM FEES								
				Extra Claims		Fee From Below		Fee Paid
Total Claims	[]	-20 **	Equals	[0]	Times	[]	Equals	\$ 0.00
Independent Claims	[]	-3 **	Equals	[0]	Times	[]	Equals	\$ 0.00
Subtotal (2)								\$ 0.00
** or number previously paid, if greater, For Reissues, see below								
	Large Entity		Small Entity		Fee Description			
	Fee Code	Fee (\$)	Fee Code	Fee (\$)				
	103		203		Claims in excess of 20			
	102		202		Independent claims in excess of 3			
	104		204		Multiple dependent claim, if not paid			
	109		209		** Reissue independent claims over original patent			
	110		210		** Reissue claims in excess of 20 and over original patent			

3. ADDITIONAL FEES					
Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
105		205		Surcharge - late filing fee or oath	\$
127		227		Surcharge - late provisional filing fee or cover sheet	\$
139		139		Non-English specification	\$
147		147		For filing a request for reexamination	\$
112		112		Requesting publication of SIR prior to Examiner action	\$
113		113		Requesting publication of SIR after Examiner action	\$
115		215		Extension for reply within first month	\$
116		216		Extension for reply within second month	\$
117		217		Extension for reply within third month	\$
118		218		Extension for reply within fourth month	\$
128		228		Extension for reply within fifth month	\$
119		219		Notice of Appeal	\$
120		220		Filing a brief in support of an appeal	\$
121		221		Request for oral hearing	\$
138		138		Petition to institute a public use proceeding	\$
140		240		Petition or revive - unavoidable	\$
141		241		Petition or revive - unintentional	\$
142		242		Utility issue fee (or reissue)	\$
143		243		Design issue fee	\$
144		244		Plant issue fee	\$
122		122		Petitions to the Commissioner	\$
123		123		Petitions related to provisional applications	\$
126		126		Submission of Information Disclosure Statement	\$
581		581		Recording each patent assignment per property	\$
146		246		Filing a submission after final rejection (37 C.F.R. 1.129(a))	\$
149		249		For each additional invention to be examined (37 CFR 1.129(b))	\$
Other fee (specify):					\$
				Subtotal (3)	\$ 0.00

4. SUMMATION OF FEES	
SUBTOTAL (1)	\$ 0.00
SUBTOTAL (2)	\$ 0.00
SUBTOTAL (3)	\$ 0.00
TOTAL FEES	\$ 0.00

SUBMITTED BY			Complete (If Applicable)	
Typed or Printed Name	David R. Preston		Registration Number:	38,710
Signature		Date: 8/30/01	Deposit Account User ID Number	50132



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Docket Number: PUR-00114.P.1.1	Application Number: 09/832,621
	Applicant: Raucy	
	Filing Date: April 11, 2001	Group Art Unit: To Be Determined


RECEIVED

MAR 19 2002

Technology Center 2100

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	P1	5,100,779	3/31/92	Watkins			
	P2	5,401,629	3/28/95	Harpold et al.			
	P3	5,670,113	9/23/97	Akong et al.			
	P4	5,707,800	1/13/98	Mangelsdorf et al.			
	P5	5,726,041	3/10/98	Chrespi et al.			
	P6	5,811,231	9/22/98	Farr et al.			
	P7	5,861,274	1/19/99	Evans et al.			
	P8	5,902,726	5/11/99	Kliewer et al.			
	P9	5,939,442	8/17/99	Evans et al.			
	P10	5,994,554	11/30/99	Kliewer et al.			
	P11	6,022,897	2/8/00	Evans et al.			
	P12	6,057,114	5/2/00	Akong et al.			
	P13	6,063,630	05/16/00	Treco et al.			
	P14	6,124,282	9/26/00	Sellers et al.			
	P15	6,187,305	2/13/01	Treco et al.			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	Translation	
							YES	NO
	F1	WO 92/16658	10/1/92	PCT				
	F2	WO 93/11235	6/10/93	PCT				
	F3	WO 94/24301	10/27/94	PCT				
	F4	WO 96/01317 A2	1/18/96	PCT				
	F5	WO 96/01317 A3	1/18/96	PCT				
	F6	WO 98/13353	04/02/98	PCT				
	F7	WO 98/52047	11/19/98	PCT				
	F8	WO 99/35246	7/15/99	PCT				
	F9	WO 99/48915	9/30/99	PCT				
	F10	WO 00/37077	6/29/00	PCT				

RECEIVED
MAR 19 2002
Technology Center 2100

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



RECEIVED

MAR 19 2002

Technology Center 2100

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
EXAMINER INITIALS		CITATION
	D1	Alam and Cook, Anal. Biochem., 188:245-254 (1990)
	D2	Ball et al., Clinical Pharmacology & Therapeutics, 66:288-294 (1999)
	D3	Beard et al., Mutation Res., 371:1-13 (1996)
	D4	Bertilsson et al., Proc. Natl. Acad. Sci. USA, 95:12208-12213 (1998)
	D5	Brockmüller et al., Toxicol. Lett., 102-103:173-183 (1998)
	D6	Casper et al., Mol. Pharmacol., 56:784-790 (1999)
	D7	Ciolino et al., Cancer Res., 58:5707-5712 (1998)
	D8	Diaz et al., Gastroenterology, 99:737-747 (1990)
	D9	Fontana et al., Gastroenterology, 117:89-98 (1999)
	D10	Garattini, Drug Metab. Rev., 29:853-886 (1997)
	D11	Goodwin et al., Mol. Pharmacol., 56:1329-1339 (1999)
	D12	Hirth et al., Clin. Cancer Res., 6:1255-1258 (2000)
	D13	Honkakoski et al., Biochem. J., 347:321-337 (2000)
	D14	Ito et al., Annu. Rev. Pharmacol. Toxicol., 38:461-499 (1998)
	D15	Jones et al., Environ. Toxicol. Pharmacol., 8:199-126 (2000)
	D16	Jones et al., Mol. Endocrinol., 14:27-39 (2000)
	D17	Kedderis, Chemico-Biological Interact., 107:109-121(1997)
	D18	Kostrubsky et al., Drug Met. Dispos., 27:887-894 (1999)
	D19	Lan et al., Mol. Pharmacol., 58:863-869 (2000)
	D20	Lee et al., Cancer Res., 57:1575-1579 (1997)
	D21	Lehman et al., J. Clin. Invest., 102:1016-1023 (1998)
	D22	MacGregor et al., Fundamental and Appl. Toxicology, 26:156-173 (1995)
	D23	McCune et al., Clin. Pharmacol. Therapeutics, 68:356-366 (2000)
	D24	Moore and Kliever, Toxicology, 153:1-10 (2000)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



RECEIVED

MAR 19 2002

Technology Center 2100

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
EXAMINER INITIALS		CITATION
	D25	Moore et al., Proc. Natl. Acad. Sci. USA, 97:7500-7502 (2000)
	D26	Munzel et al., Drug Met. Dispos., 27:569-573 (1999)
	D27	Nebert and Dieter, Pharmacology, 61:124-135 (2000)
	D28	Nebert and Gonzalez, Ann. Rev. Biochem., 56:945-993 (1987)
	D29	Nelson et al., DNA Cell Biol., 12:1-51 (1993)
	D30	Parker et al., J. Clin. Endocrinol. and Metabol., 80:1027-1031 (1995)
	D31	Pascussi et al., Mol. Pharmacol., 58:361-372 (2000)
	D32	Plant et al., Analyt. Biochem., 278:170-174 (2000)
	D33	Postlind et al., Toxicol. Appl. Pharmacol., 118:255-262 (1993)
	D34	Quattrochi and Guzelian., Drug Metabol. Dispos., 29:615-622 (2001)
	D35	Quattrochi and Tukey, Mol. Pharmacol., 43:504-508 (1993)
	D36	Quattrochi et al., DNA, 4:395-400 (1985)
	D37	Quattrochi et al., J. Biol. Chem., 270:28917-28923 (1995)
	D38	Rodrigo et al., Scand. J. Gastroenterol., 34:303-307 (1999)
	D39	Rodrigues, Pharm. Res., 14:1504-1510 (1997)
	D40	Rost et al., Clin. Pharmacol. Ther., 52:170-180 (1992)
	D41	Runge et al., Biochem. Biophys. Res. Commun., 273:333-341 (2000)
	D42	Savas et al., Mol. Pharmacol., 56:851-857 (1999)
	D43	Schuetz and Strom, Nature Medicine, 7:536-537 (2001)
	D44	Schuetz et al., J. Cell. Physiol., 165:261-272 (1995)
	D45	Schuetz et al., Mol. Pharmacol., 49:311-318 (1996)
	D46	Shih et al., Hum. Exper. Toxicol., 18:95-105 (1999)
	D47	Synold et al., Nature Medicine, 7:584-589 (2001)
	D48	Todd et al., Fundamental and Appl. Toxicology, 28:118-128 (1995)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



RECEIVED

MAR 19 2002

Technology Center 2100

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
EXAMINER INITIALS		CITATION
	D49	Vaury et al., Cancer Res., 55:5520-5523 (1995)
	D50	Watkins et al., Clin. Pharmacol. Ther., 265-273 (1992)
	D51	Williams et al., J. Inorganic Biochem., 81:183-190 (2000)
	D52	Windmill et al., Mutat. Res., 376:153-160 (1997)
	D53	Wrighton et al., Drug Metab. Rev., 32:339-361 (2000)
	D54	Xie et al., Genes and Develop., 14:3014-3023 (2000)
	D55	Xie et al., Nature, 406:435-439 (2000)
	D56	Ziccardii et al., Toxicol. Sci. 54:183-193 (2000)
	D57	Materials from Xenometrix - Internet Homepage (August 14, 2001) www.xeno.com

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--